

COVID-19 Vaccine Schedule

COVID-19 vaccines available in Alberta for 2024-2025:

- Moderna Spikevax KP.2 COVID-19 vaccine (6 months of age and older)
- Pfizer-BioNTech KP.2 COVID-19 vaccine (12 years of age and older)

TABLE 1: KP.2 DOSES FOR INDIVIDUALS WHO ARE NOT IMMUNOCOMPROMISED

Age Group	COVID-19 Immunization History	Recommended KP.2 COVID-19 vaccine doses	FIRST dose of KP.2 COVID-19 vaccine	SECOND dose of KP.2 COVID-19 vaccine
5 years of age and older	Received 1 or more previous non-KP.2 doses	1	At least <u>3 months</u> from previous non-KP.2 dose	
	Unimmunized	1	As soon as you can	
6 months to 4 years of age	Received 2 or more previous non-KP.2 doses	1	At least <u>3 months</u> from previous non-KP.2 dose	
	Received 1 previous non-KP.2 dose	1	<u>8 weeks</u> from last non-KP.2 dose	
	Unimmunized	2	As soon as you can	

Notes

- **COVID-19 immunization history** refers to any previous dose(s) of mRNA vaccines (original monovalent, bivalent or XBB.1.5 Moderna or Pfizer-BioNTech) and non-mRNA COVID-19 vaccines (AstraZeneca, Janssen, Novavax, and WHO-approved COVID-19 vaccines). If you received a COVID-19 vaccine not approved by Health Canada, please call Health Link (811).
- **Vaccine after infection:** It is recommended that the COVID-19 vaccine be delayed for those who have tested positive for COVID-19 (by PCR or rapid antigen test). See [Table 3](#) below for more details. If you have questions, please call Health Link (811), or ask your healthcare provider.

COVID-19 Vaccine Schedule

TABLE 2: KP.2 DOSES FOR INDIVIDUALS WHO ARE IMMUNOCOMPROMISED

Immunocompromised individuals should follow the schedule below and receive the appropriate number of KP.2 COVID-19 vaccine to complete a three-dose COVID-19 vaccine series. Regardless of whether they have received one or two non-KP.2 COVID-19 vaccine doses, the previous dose(s) should be counted, and the series should not be restarted.

Age Group	COVID-19 Immunization History	Recommended KP.2 COVID-19 vaccine doses	FIRST dose of KP.2 COVID-19 vaccine	SECOND dose of KP.2 COVID-19 vaccine	THIRD dose of KP.2 COVID-19 vaccine
6 months of age and older	Received 3 or more previous doses of non-KP.2 vaccine doses	1	At least 3 months from previous non-KP.2 dose		
	Received 2 previous doses of non-KP.2 vaccine doses	1	8 weeks from last non-KP.2 dose*		
	Received 1 previous dose of non-KP.2 vaccine dose	2	4 weeks from previous non-KP.2 COVID-19 vaccine dose	8 weeks from previous non-KP.2 COVID-19 vaccine dose*	
	Unimmunized	3	As soon as you can	4 weeks after FIRST dose of KP.2 COVID-19 vaccine	8 weeks after SECOND dose of KP.2 COVID-19 vaccine*

*A 4-week interval may be considered.

Notes

- A list of eligible immunocompromising conditions can be found [here](#).
- **COVID-19 vaccines available in Alberta for 2024-2025:**
 - Moderna Spikevax KP.2 COVID-19 vaccine (6 months of age and older)
 - Pfizer-BioNTech KP.2 COVID-19 vaccine (12 years of age and older)
- **COVID-19 immunization history** refers to any previous dose(s) of mRNA vaccines (original monovalent, bivalent or XBB.1.5 Moderna, Pfizer-BioNTech) and non-mRNA COVID-19 vaccines (AstraZeneca, Janssen, Novavax, and WHO-approved COVID-19 vaccines). If you received a COVID-19 vaccine that is not approved by Health Canada, please call Health Link (811).
- Hematopoietic stem cell transplants recipients – pre-transplant and post-transplant while in immunosuppressed state and individuals receiving Chimeric Antigen Receptor T-Cell Therapy (CAR T-cell therapy), please see:
 - [Principles of Immunization in Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients](#)
 - [Child HSCT](#)
 - [Adult HSCT](#)

COVID-19 Vaccine Schedule

- **Vaccine after infection:** It is recommended that the COVID-19 vaccine be delayed for those who have tested positive for COVID-19 (by PCR or rapid antigen test). See [Table 3](#) below for more details. If you have questions, please call Health Link (811), or ask your healthcare provider.

TABLE 3: KP.2 DOSES – SPACING POST-INFECTION

NOT IMMUNOCOMPROMISED		
Age group	Vaccine history	Interval between dose and positive COVID-19 test
5 years and older	Any	3 months
6 months to 4 years	Two or more previous doses	3 months
	One previous dose	8 weeks
	Unimmunized	8 weeks
IMMUNOCOMPROMISED		
Age group	Vaccine history	Interval between dose and positive COVID-19 test
6 months and older	Three or more previous doses	3 months
	One or two previous doses	4 – 8 weeks
	Unimmunized	4 – 8 weeks

Notes

- For individuals with a history of multisystem inflammatory syndrome in children (MIS-C), please consult your primary care provider.